Russell Investments Group Ltd. grew its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Rating) by 21.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,910 shares of the company's stock after buying an additional 6,900 shares during the quarter. Russell Investments Group Ltd.'s holdings in Organogenesis were worth $295,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C lifted its position in Organogenesis by 13.3% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,456,876 shares of the company's stock worth $78,142,000 after buying an additional 994,333 shares in the last quarter. Soleus Capital Management L.P. lifted its position in Organogenesis by 212.4% during the 4th quarter. Soleus Capital Management L.P. now owns 1,999,087 shares of the company's stock worth $18,472,000 after buying an additional 1,359,200 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Organogenesis by 29.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,650,642 shares of the company's stock worth $12,578,000 after buying an additional 380,389 shares in the last quarter. Principal Financial Group Inc. lifted its position in Organogenesis by 0.5% during the 4th quarter. Principal Financial Group Inc. now owns 500,077 shares of the company's stock worth $4,621,000 after buying an additional 2,630 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Organogenesis by 0.6% during the 4th quarter. Northern Trust Corp now owns 471,869 shares of the company's stock worth $4,360,000 after buying an additional 2,621 shares in the last quarter. 38.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ORGO. BTIG Research cut their price target on shares of Organogenesis to $13.00 in a research report on Monday, August 15th. Oppenheimer cut shares of Organogenesis from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 10th.

Organogenesis Stock Down 0.5 %

Insider Activity

In other news, CEO Gary S. Gillheeney sold 56,362 shares of the company's stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $5.93, for a total value of $334,226.66. Following the sale, the chief executive officer now directly owns 398,242 shares of the company's stock, valued at approximately $2,361,575.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Organogenesis news, CEO Gary S. Gillheeney sold 56,362 shares of the stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $5.93, for a total value of $334,226.66. Following the transaction, the chief executive officer now directly owns 398,242 shares of the company's stock, valued at approximately $2,361,575.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Gary S. Gillheeney sold 116,608 shares of the stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $5.58, for a total transaction of $650,672.64. Following the completion of the transaction, the chief executive officer now directly owns 398,242 shares in the company, valued at $2,222,190.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 431,879 shares of company stock valued at $2,399,264. 34.40% of the stock is owned by company insiders.

Organogenesis Company Profile

(Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Read More

• Get a free copy of the StockNews.com research report on Organogenesis (ORGO)
• Are Ocugen or Amarin Good Penny Stocks to Buy?
• Are These 2 Fintechs A Buy After Q2 Earnings?
• Is Fisker Ready to Re-Emerge as the Tesla Killer?
• Chipotle is Cooking Up Another Run at $2,000
• Dick's Sporting Goods Lifted By Institutional Shift

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Rating).

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.